Deutsche Bank AG Purchases Shares of 162,533 Guardant Health, Inc. $GH

Deutsche Bank AG acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, Holdings Channel reports. The fund acquired 162,533 shares of the company’s stock, valued at approximately $24,385,000.

A number of other hedge funds have also modified their holdings of GH. GAMMA Investing LLC raised its position in Guardant Health by 14.5% in the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after buying an additional 122 shares during the last quarter. First Pacific Financial boosted its position in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC grew its stake in shares of Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after acquiring an additional 199 shares in the last quarter. Danske Bank A S raised its holdings in shares of Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares during the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna raised its holdings in shares of Guardant Health by 1.9% in the fourth quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after purchasing an additional 200 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CEO Amirali Talasaz sold 143,028 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the transaction, the chief executive officer owned 1,881,336 shares in the company, valued at approximately $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 63,605 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total value of $10,786,135.90. Following the completion of the sale, the insider owned 65,374 shares of the company’s stock, valued at $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 521,818 shares of company stock valued at $77,539,233 in the last ninety days. 5.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages recently commented on GH. TD Cowen increased their target price on shares of Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Guggenheim increased their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. The Goldman Sachs Group restated a “buy” rating and issued a $210.00 price objective on shares of Guardant Health in a report on Friday, July 31st. Finally, UBS Group set a $150.00 target price on Guardant Health in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average price target of $183.78.

Guardant Health Price Performance

Shares of GH opened at $170.69 on Friday. The company’s 50-day moving average is $153.91 and its 200-day moving average is $118.69. The firm has a market capitalization of $22.91 billion, a PE ratio of -48.91 and a beta of 1.60. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. The firm’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.44) EPS. Analysts predict that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.